Allakos Inc (NASDAQ:ALLK) – Equities research analysts at Jefferies Financial Group raised their FY2019 EPS estimates for shares of Allakos in a note issued to investors on Wednesday, November 13th. Jefferies Financial Group analyst M. Raycroft now forecasts that the company will post earnings of ($1.88) per share for the year, up from their previous estimate of ($1.91). Jefferies Financial Group also issued estimates for Allakos’ FY2020 earnings at ($2.17) EPS, FY2021 earnings at ($2.86) EPS, FY2022 earnings at ($3.53) EPS and FY2023 earnings at ($2.82) EPS.
Allakos (NASDAQ:ALLK) last posted its earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.04).
ALLK opened at $72.72 on Monday. The company has a market capitalization of $3.71 billion, a price-to-earnings ratio of -33.05 and a beta of -1.38. The firm has a 50-day moving average price of $73.05 and a 200-day moving average price of $59.64. Allakos has a twelve month low of $30.32 and a twelve month high of $92.84.
Large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC purchased a new position in Allakos during the third quarter valued at approximately $42,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Allakos during the third quarter valued at approximately $113,000. Bank of Montreal Can purchased a new position in Allakos during the second quarter valued at approximately $63,000. Amundi Pioneer Asset Management Inc. purchased a new position in Allakos during the first quarter valued at approximately $142,000. Finally, SG Americas Securities LLC grew its stake in Allakos by 27.5% during the second quarter. SG Americas Securities LLC now owns 4,819 shares of the company’s stock valued at $209,000 after acquiring an additional 1,040 shares in the last quarter. 58.47% of the stock is owned by institutional investors.
Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
See Also: Different Options Trading Strategies
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.